secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2026-08-10T11:15:14+00:00
Accession:  0001213900-26-086939
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake Phase 3 IZAR-1 meets all endpoints; Q2 cash $537M, runway to mid-2028
------------------------------------------------------------------------------

- IZAR-1 Week 16: ACR50 42.1%, ACR20 66.5%, MDA 41.2%, PASI90 61% for sonelokimab 60mg.
- Q2 2026 cash $537.0M; expects runway to mid-2028; up to $400M non-dilutive from Hercules.
- Q2 R&D expenses $50.2M vs $54.5M in Q1; G&A $11.4M vs $15.5M in Q1.
- IZAR-1 continues to Week 52; full readout H1 2027; IZAR-2 enrollment completion expected Q3 2026.
- HS BLA submission expected end Sep 2026; PDUFA date allocation and Priority Review decision end Nov 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/0001213900-26-086939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea0301191-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-086939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer